The DOI matches its Crossref record; 161 of the 161 references it cites were found in a registry or an index.
Non-alcoholic fatty liver disease (NAFLD) – pathogenesis, classification, and effect on drug metabolizing enzymes and transporters
Open accessAbstract
Non-alcoholic fatty liver disease (NAFLD) is a spectrum of liver disorders. It is defined by the presence of steatosis in more than 5% of hepatocytes with little or no alcohol consumption. Insulin resistance, the metabolic syndrome or type 2 diabetes and genetic variants of PNPLA3 or TM6SF2 seem to play a role in the pathogenesis of NAFLD. The pathological progression of NAFLD follows tentatively a "three-hit" process namely steatosis, lipotoxicity and inflammation. The presence of steatosis, oxidative stress and inflammatory mediators like TNF-α and IL-6 has been implicated in the alterations of nuclear factors such as CAR, PXR, PPAR-α in NAFLD. These factors may result in altered expression and activity of drug metabolizing enzymes (DMEs) or transporters. Existing evidence suggests that the effect of NAFLD on CYP3A4, CYP2E1 and MRP3 is more consistent across rodent and human studies. CYP3A4 activity is down-regulated in NASH whereas the activity of CYP2E1 and the efflux transporter MRP3 is up-regulated. However, it is not clear how the majority of CYPs, UGTs, SULTs and transporters are influenced by NAFLD either in vivo or in vitro. The alterations associated with NAFLD could be a potential source of drug variability in patients and could have serious implications for the safety and efficacy of xenobiotics. In this review, we summarize the effects of NAFLD on the regulation, expression and activity of major DMEs and transporters. We also discuss the potential mechanisms underlying these alterations.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Alberti, K. G. M. M., Eckel, R. H., Grundy, S. M., Zimmet, P. Z., Cleeman, J. I., Donato, K. A., Fruchart, J.-C., James, W. P. T., Loria, C. M., & Smith, S. C. (2009) · Circulation · doi:10.1161/circulationaha.109.192644 · Cited by 14,860
Design and validation of a histological scoring system for nonalcoholic fatty liver disease†
Kleiner, D. E., Brunt, E. M., Van Natta, M., Behling, C., Contos, M. J., Cummings, O. W., Ferrell, L. D., Liu, Y., Torbenson, M. S., Unalp‐Arida, A., et al. (2005) · Hepatology · doi:10.1002/hep.20701 · Cited by 10,791 · cited 4×
“Additionally, it was not designed to evaluate NAFLD in children (Kleiner et al., 2005).”
BackgroundMethodInfluentialEckel, R. H., Alberti, K., Grundy, S. M., & Zimmet, P. Z. (2010) · The Lancet · doi:10.1016/s0140-6736(09)61794-3 · Cited by 6,295
Nonalcoholic Fatty Liver Disease
Angulo, P. (2002) · New England Journal of Medicine · doi:10.1056/nejmra011775 · Cited by 5,228
Zanger, U. M., & Schwab, M. (2013) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2012.12.007 · Cited by 4,169 · cited 11×
“1 and includes four genes – 3A4, 3A5, 3A7 and 3A43 (Zanger & Schwab, 2013).”
BackgroundInfluentialNonalcoholic Steatohepatitis: A Proposal for Grading and Staging The Histological Lesions
Brunt, E. M., Janney, C. G., Di Bisceglie, A. M., Neuschwander-Tetri, B. A., & Bacon, B. R. (1999) · American Journal of Gastroenterology · doi:10.1111/j.1572-0241.1999.01377.x · Cited by 3,907
Prevalence of Hepatic Steatosis in An Urban Population in the United States: Impact of Ethnicity
Browning, J. D., Szczepaniak, L. S., Dobbins, R., Nuremberg, P., Horton, J. D., Cohen, J. C., Grundy, S. M., & Hobbs, H. H. (2004) · Hepatology · doi:10.1002/hep.20466 · Cited by 3,664
Hayes, J. D., Flanagan, J. U., & Jowsey, I. R. (2005) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.45.120403.095857 · Cited by 3,544
Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease
Romeo, S., Kozlitina, J., Xing, C., Pertsemlidis, A., Cox, D., Pennacchio, L. A., Boerwinkle, E., Cohen, J. C., & Hobbs, H. H. (2008) · Nature Genetics · doi:10.1038/ng.257 · Cited by 3,416
Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity.
MATTEONI, C., YOUNOSSI, Z., GRAMLICH, T., BOPARAI, N., LIU, Y., & MCCULLOUGH, A. (1999) · Gastroenterology · doi:10.1016/s0016-5085(99)70506-8 · Cited by 3,345
Membrane transporters in drug development
The International Transporter Consortium, Giacomini, K. M., Huang, S.-M., Tweedie, D. J., Benet, L. Z., Brouwer, K. L. R., Chu, X., Dahlin, A., Evers, R., Fischer, V., et al. (2010) · Nature Reviews Drug Discovery · doi:10.1038/nrd3028 · Cited by 3,340
Cellular mechanisms of insulin resistance
Shulman, G. I. (2000) · Journal of Clinical Investigation · doi:10.1172/jci10583 · Cited by 2,714
Cornier, M.-A., Dabelea, D., Hernandez, T. L., Lindstrom, R. C., Steig, A. J., Stob, N. R., Van Pelt, R. E., Wang, H., & Eckel, R. H. (2008) · Endocrine Reviews · doi:10.1210/er.2008-0024 · Cited by 2,162
Sampling Variability of Liver Biopsy in Nonalcoholic Fatty Liver Disease
Ratziu, V., Charlotte, F., Heurtier, A., Gombert, S., Giral, P., Bruckert, E., Grimaldi, A., Capron, F., & Poynard, T. (2005) · Gastroenterology · doi:10.1053/j.gastro.2005.03.084 · Cited by 2,106 · cited 1×
“Able to detect steatosis and inflammation (Ratziu et al., 2005; Wieckowska & Feldstein, 2008) 200 E.”
BackgroundNonalcoholic steatohepatitis: association of insulin resistance and mitochondrial abnormalities
Sanyal, A. J., Campbell–Sargent, C., Mirshahi, F., Rizzo, W. B., Contos, M. J., Sterling, R. K., Luketic, V. A., Shiffman, M. L., & Clore, J. N. (2001) · Gastroenterology · doi:10.1053/gast.2001.23256 · Cited by 2,078
Molecular mediators of hepatic steatosis and liver injury
Browning, J. D., & Horton, J. D. (2004) · Journal of Clinical Investigation · doi:10.1172/jci200422422 · Cited by 1,772
Cytochrome P450 and Chemical Toxicology
Guengerich, F. P. (2008) · Chemical Research in Toxicology · doi:10.1021/tx700079z · Cited by 1,725
Independent predictors of liver fibrosis in patients with nonalcoholic steatohepatitis
Angulo, P., Keach, J. C., Batts, K. P., & Lindor, K. D. (1999) · Hepatology · doi:10.1002/hep.510300604 · Cited by 1,610
Association of nonalcoholic fatty liver disease with insulin resistance
Marchesini, G., Brizi, M., Morselli-Labate, A. M., Bianchi, G., Bugianesi, E., McCullough, A. J., Forlani, G., & Melchionda, N. (1999) · The American Journal of Medicine · doi:10.1016/s0002-9343(99)00271-5 · Cited by 1,568
Dixon, J. B., Bhathal, P. S., & O'Brien, P. E. (2001) · Gastroenterology · doi:10.1053/gast.2001.25540 · Cited by 1,360
Nonalcoholic Fatty Liver Disease and Hepatocellular Carcinoma: A Weighty Connection
Starley, B. Q., Calcagno, C. J., & Harrison, S. A. (2010) · Hepatology · doi:10.1002/hep.23594 · Cited by 1,336
The economic and clinical burden of nonalcoholic fatty liver disease in the United States and Europe
Younossi, Z. M., Blissett, D., Blissett, R., Henry, L., Stepanova, M., Younossi, Y., Racila, A., Hunt, S., & Beckerman, R. (2016) · Hepatology · doi:10.1002/hep.28785 · Cited by 1,285
CYTOCHROME P-450 3A4: Regulation and Role in Drug Metabolism
Guengerich, F. P. (1999) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.39.1.1 · Cited by 1,267
Nrf2 signaling in coordinated activation of antioxidant gene expression
Jaiswal, A. K. (2004) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2004.02.074 · Cited by 1,254
Brunt, E. M., Kleiner, D. E., Wilson, L. A., Belt, P., & Neuschwander-Tetri, B. A. (2011) · Hepatology · doi:10.1002/hep.24127 · Cited by 1,251
Mofrad, P., Contos, M. J., Haque, M., Sargeant, C., Fisher, R. A., Luketic, V. A., Sterling, R. K., Shiffman, M. L., Stravitz, R. T., & Sanyal, A. J. (2003) · Hepatology · doi:10.1053/jhep.2003.50229 · Cited by 1,201
Ingelman-Sundberg, M. (2005) · The Pharmacogenomics Journal · doi:10.1038/sj.tpj.6500285 · Cited by 1,108
Mechanistic Studies of the Nrf2-Keap1 Signaling Pathway
Zhang, D. D. (2006) · Drug Metabolism Reviews · doi:10.1080/03602530600971974 · Cited by 1,086
Liver fibrosis in overweight patients
Ratziu, V., Giral, P., Charlotte, F., Bruckert, E., Thibault, V., Theodorou, I., Khalil, L., Turpin, G., Opolon, P., & Poynard, T. (2000) · Gastroenterology · doi:10.1016/s0016-5085(00)70364-7 · Cited by 973
Intrahepatic fat, not visceral fat, is linked with metabolic complications of obesity
Fabbrini, E., Magkos, F., Mohammed, B. S., Pietka, T., Abumrad, N. A., Patterson, B. W., Okunade, A., & Klein, S. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0904944106 · Cited by 972
Williams, J. A., Hyland, R., Jones, B. C., Smith, D. A., Hurst, S., Goosen, T. C., Peterkin, V., Koup, J. R., & Ball, S. E. (2004) · Drug Metabolism and Disposition · doi:10.1124/dmd.104.000794 · Cited by 928
Sookoian, S., & Pirola, C. J. (2011) · Hepatology · doi:10.1002/hep.24283 · Cited by 920
Bedossa, P., Poitou, C., Veyrie, N., Bouillot, J.-L., Basdevant, A., Paradis, V., Tordjman, J., & Clement, K. (2012) · Hepatology · doi:10.1002/hep.25889 · Cited by 903
Nonalcoholic Fatty Liver Disease: Pathology and Pathogenesis
Tiniakos, D. G., Vos, M. B., & Brunt, E. M. (2010) · Annual Review of Pathology: Mechanisms of Disease · doi:10.1146/annurev-pathol-121808-102132 · Cited by 870
Endpoints and clinical trial design for nonalcoholic steatohepatitis
Sanyal, A. J., Brunt, E. M., Kleiner, D. E., Kowdley, K. V., Chalasani, N., Lavine, J. E., Ratziu, V., & McCullough, A. (2011) · Hepatology · doi:10.1002/hep.24376 · Cited by 750
Pharmacogenetics of morphine poisoning in a breastfed neonate of a codeine-prescribed mother
Koren, G., Cairns, J., Chitayat, D., Gaedigk, A., & Leeder, S. J. (2006) · The Lancet · doi:10.1016/s0140-6736(06)69255-6 · Cited by 684
Jiang, W., Wu, N., Wang, X., Chi, Y., Zhang, Y., Qiu, X., Hu, Y., Li, J., & Liu, Y. (2015) · Scientific Reports · doi:10.1038/srep08096 · Cited by 649
Clinical Pharmacokinetics of Atorvastatin
Lennern??s, H. (2003) · Clinical Pharmacokinetics · doi:10.2165/00003088-200342130-00005 · Cited by 623
The epidemiology of non‐alcoholic fatty liver disease
Bellentani, S. (2017) · Liver International · doi:10.1111/liv.13299 · Cited by 606
Nonalcoholic Fatty Liver Disease in Lean Individuals in the United States
Younossi, Z. M., Stepanova, M., Negro, F., Hallaji, S., Younossi, Y., Lam, B., & Srishord, M. (2012) · Medicine · doi:10.1097/md.0b013e3182779d49 · Cited by 559
Dongiovanni, P., Petta, S., Maglio, C., Fracanzani, A. L., Pipitone, R., Mozzi, E., Motta, B. M., Kaminska, D., Rametta, R., Grimaudo, S., et al. (2015) · Hepatology · doi:10.1002/hep.27490 · Cited by 533 · cited 2×
“…variant of the lipid transporter located on ER (endoplasmic reticulum) and ER-Golgi compartments, TM6SF2 (transmembrane 6 superfamily member 2), encoding E167K (rs58542926 C/T), causes loss of function of the protein and increases hepatic deposition of triglycerides (Dongiovanni et al., 2015).”
BackgroundSex Is A Major Determinant of Cyp3a4 Expression in Human Liver
Wolbold, R., Klein, K., Burk, O., Nüssler, A. K., Neuhaus, P., Eichelbaum, M., Schwab, M., & Zanger, U. M. (2003) · Hepatology · doi:10.1002/hep.1840380424 · Cited by 529
Sayiner, M., Koenig, A., Henry, L., & Younossi, Z. M. (2016) · Clinics in Liver Disease · doi:10.1016/j.cld.2015.10.001 · Cited by 529
EASL-EASD-EASO Clinical Practice Guidelines for the Management of Non-Alcoholic Fatty Liver Disease
European Association for the Study of the Liver (EASL), E. A. F. T. S. O. D. (. (2016) · Obesity Facts · doi:10.1159/000443344 · Cited by 521
Oxidative Stress, Toxicology, and Pharmacology of CYP2E1
Caro, A. A., & Cederbaum, A. I. (2004) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.44.101802.121704 · Cited by 512
Impact of Drug Transporter Studies on Drug Discovery and Development
Mizuno, N., Niwa, T., Yotsumoto, Y., & Sugiyama, Y. (2003) · Pharmacological Reviews · doi:10.1124/pr.55.3.1 · Cited by 490
The natural history of nonalcoholic fatty liver disease: a clinical histopathological study
Harrison, S. (2003) · The American Journal of Gastroenterology · doi:10.1016/s0002-9270(03)00622-1 · Cited by 482
Mechanisms of Disease Progression in Nonalcoholic Fatty Liver Disease
Jou, J., Choi, S., & Diehl, A. (2008) · Seminars in Liver Disease · doi:10.1055/s-0028-1091981 · Cited by 482
Fatty Acid Regulation of Hepatic Gene Transcription
Jump, D. B., Botolin, D., Wang, Y., Xu, J., Christian, B., & Demeure, O. (2005) · The Journal of Nutrition · doi:10.1093/jn/135.11.2503 · Cited by 477
Morgan, E. (2009) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2008.302 · Cited by 462
REGULATION OF DRUG-METABOLIZING ENZYMES AND TRANSPORTERS IN INFLAMMATION
Aitken, A. E., Richardson, T. A., & Morgan, E. T. (2006) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.46.120604.141059 · Cited by 448
N-3 polyunsaturated fatty acid regulation of hepatic gene transcription
Jump, D. B. (2008) · Current Opinion in Lipidology · doi:10.1097/mol.0b013e3282ffaf6a · Cited by 443
Bugianesi, E., Manzini, P., D'Antico, S., Vanni, E., Longo, F., Leone, N., Massarenti, P., Piga, A., Marchesini, G., & Rizzetto, M. (2004) · Hepatology · doi:10.1002/hep.20023 · Cited by 440
Epidemiology and natural history of non-alcoholic fatty liver disease
Fazel, Y., Koenig, A. B., Sayiner, M., Goodman, Z. D., & Younossi, Z. M. (2016) · Metabolism · doi:10.1016/j.metabol.2016.01.012 · Cited by 433
Nonalcoholic Fatty Liver Disease: An Underrecognized Cause of Cryptogenic Cirrhosis
Clark, J. M., & Diehl, A. M. (2003) · JAMA · doi:10.1001/jama.289.22.3000 · Cited by 428
Gene expression in human NAFLD
Greco, D., Kotronen, A., Westerbacka, J., Puig, O., Arkkila, P., Kiviluoto, T., Laitinen, S., Kolak, M., Fisher, R. M., Hamsten, A., et al. (2008) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.00074.2008 · Cited by 427
CAR and PXR: The xenobiotic-sensing receptors☆
Timsit, Y. E., & Negishi, M. (2007) · Steroids · doi:10.1016/j.steroids.2006.12.006 · Cited by 423
Characteristics of Patients With Nonalcoholic Steatohepatitis Who Develop Hepatocellular Carcinoma
Yasui, K., Hashimoto, E., Komorizono, Y., Koike, K., Arii, S., Imai, Y., Shima, T., Kanbara, Y., Saibara, T., Mori, T., et al. (2011) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2011.01.023 · Cited by 420
Palmitic acid induces production of proinflammatory cytokine interleukin-8 from hepatocytes
Joshi-Barve, S., Barve, S. S., Amancherla, K., Gobejishvili, L., Hill, D., Cave, M., Hote, P., & McClain, C. J. (2007) · Hepatology · doi:10.1002/hep.21752 · Cited by 406
Aitken, A. E., & Morgan, E. T. (2007) · Drug Metabolism and Disposition · doi:10.1124/dmd.107.015511 · Cited by 398
Weltman, M., Farrell, G., & Liddle, C. (1996) · Gastroenterology · doi:10.1016/s0016-5085(96)70028-8 · Cited by 397
Epidemiology and Natural History of Non-Alcoholic Steatohepatitis
Argo, C. K., & Caldwell, S. H. (2009) · Clinics in Liver Disease · doi:10.1016/j.cld.2009.07.005 · Cited by 389
Molecular Mechanisms and Therapeutic Targets in Steatosis and Steatohepatitis
Anderson, N., & Borlak, J. (2008) · Pharmacological Reviews · doi:10.1124/pr.108.00001 · Cited by 385
Management of NAFLD: a stage-based approach
Rinella, M. E., & Sanyal, A. J. (2016) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2016.3 · Cited by 385
II. Cytochrome P-450 enzymes and oxidative stress
Robertson, G., Leclercq, I., & Farrell, G. C. (2001) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.2001.281.5.g1135 · Cited by 358
Pentoxifylline improves nonalcoholic steatohepatitis: A randomized placebo-controlled trial
Zein, C. O., Yerian, L. M., Gogate, P., Lopez, R., Kirwan, J. P., Feldstein, A. E., & McCullough, A. J. (2011) · Hepatology · doi:10.1002/hep.24544 · Cited by 356
Sanyal, A. J., Friedman, S. L., McCullough, A. J., & Dimick‐Santos, L. (2015) · Hepatology · doi:10.1002/hep.27678 · Cited by 354
Fisher, C. D., Lickteig, A. J., Augustine, L. M., Ranger-Moore, J., Jackson, J. P., Ferguson, S. S., & Cherrington, N. J. (2009) · Drug Metabolism and Disposition · doi:10.1124/dmd.109.027466 · Cited by 352
Hepatic Cytochrome P450 2E1 Activity in Nondiabetic Patients With Nonalcoholic Steatohepatitis
Chalasani, N., Gorski, C. J., Asghar, M. S., Asghar, A., Foresman, B., Hall, S. D., & Crabb, D. W. (2003) · Hepatology · doi:10.1053/jhep.2003.50095 · Cited by 348
Unusual Cytochrome P450 Enzymes and Reactions
Guengerich, F. P., & Munro, A. W. (2013) · Journal of Biological Chemistry · doi:10.1074/jbc.r113.462275 · Cited by 346
BAEZ, S., SEGURA-AGUILAR, J., WIDERSTEN, M., JOHANSSON, A.-S., & MANNERVIK, B. (1997) · Biochemical Journal · doi:10.1042/bj3240025 · Cited by 340
Structure and Function of Sulfotransferases
Negishi, M., Pedersen, L. G., Petrotchenko, E., Shevtsov, S., Gorokhov, A., Kakuta, Y., & Pedersen, L. C. (2001) · Archives of Biochemistry and Biophysics · doi:10.1006/abbi.2001.2368 · Cited by 333
Gut–liver axis, nutrition, and non-alcoholic fatty liver disease
Kirpich, I. A., Marsano, L. S., & McClain, C. J. (2015) · Clinical Biochemistry · doi:10.1016/j.clinbiochem.2015.06.023 · Cited by 327
Kleiner, D. E., & Makhlouf, H. R. (2016) · Clinics in Liver Disease · doi:10.1016/j.cld.2015.10.011 · Cited by 303
Diagnosis of Nonalcoholic Fatty Liver Disease: Invasive versus Noninvasive
Wieckowska, A., & Feldstein, A. (2008) · Seminars in Liver Disease · doi:10.1055/s-0028-1091983 · Cited by 300
CYP2B6: New Insights into a Historically Overlooked Cytochrome P450 Isozyme
Wang, H., & Tompkins, L. M. (2008) · Current Drug Metabolism · doi:10.2174/138920008785821710 · Cited by 299
The Influence of Age and Sex on the Clearance of Cytochrome P450 3A Substrates
Cotreau, M. M., von Moltke, L. L., & Greenblatt, D. J. (2005) · Clinical Pharmacokinetics · doi:10.2165/00003088-200544010-00002 · Cited by 292
Aubert, J., Begriche, K., Knockaert, L., Robin, M. A., & Fromenty, B. (2011) · Clinics and Research in Hepatology and Gastroenterology · doi:10.1016/j.clinre.2011.04.015 · Cited by 282
Functional Gene Variants of CYP3A4
Werk, A. N., & Cascorbi, I. (2014) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2014.129 · Cited by 273
MicroRNAs Regulate CYP3A4 Expression via Direct and Indirect Targeting
Pan, Y.-Z., Gao, W., & Yu, A.-M. (2009) · Drug Metabolism and Disposition · doi:10.1124/dmd.109.027680 · Cited by 272
STRUCTURE AND FUNCTION OF URIDINE DIPHOSPHATE GLUCURONOSYLTRANSFERASES
Meech, R., & Mackenzie, P. I. (1997) · Clinical and Experimental Pharmacology and Physiology · doi:10.1111/j.1440-1681.1997.tb02718.x · Cited by 264
GLUCURONIDATION AND THE UDP-GLUCURONOSYLTRANSFERASES IN HEALTH AND DISEASE
Wells, P. G., Mackenzie, P. I., Roy Chowdhury, J., Guillemette, C., Gregory, P. A., Ishii, Y., Hansen, A. J., Kessler, F. K., Kim, P. M., Roy Chowdhury, N., et al. (2004) · Drug Metabolism and Disposition · doi:10.1124/dmd.32.3.281 · Cited by 260
The role of individual human cytochrpmes P450 in drug metabolism and clinical response
Cholerton, S., Daly, A. K., & Idle, J. R. (1992) · Trends in Pharmacological Sciences · doi:10.1016/0165-6147(92)90140-2 · Cited by 246
Abdelmegeed, M. A., Banerjee, A., Yoo, S.-H., Jang, S., Gonzalez, F. J., & Song, B.-J. (2012) · Journal of Hepatology · doi:10.1016/j.jhep.2012.05.019 · Cited by 241
Characterization of the cytochrome P450 enzymes involved in the in vitro metabolism of rosiglitazone
Baldwin, Clarke, & Chenery (1999) · British Journal of Clinical Pharmacology · doi:10.1046/j.1365-2125.1999.00030.x · Cited by 235
A Semi-Mechanistic Model to Predict the Effects of Liver Cirrhosis on Drug Clearance
Johnson, T. N., Boussery, K., Rowland-Yeo, K., Tucker, G. T., & Rostami-Hodjegan, A. (2010) · Clinical Pharmacokinetics · doi:10.2165/11318160-000000000-00000 · Cited by 235
Ramadori, G., & Armbrust, T. (2001) · European Journal of Gastroenterology & Hepatology · doi:10.1097/00042737-200107000-00004 · Cited by 231
A Genomic and Proteomic Study of the Spectrum of Nonalcoholic Fatty Liver Disease *
Younossi, Z. M., Baranova, A., Ziegler, K., Del Giacco, L., Schlauch, K., Born, T. L., Elariny, H., Gorreta, F., VanMeter, A., Younoszai, A., et al. (2005) · Hepatology · doi:10.1002/hep.20838 · Cited by 230
Pettinelli, P., del Pozo, T., Araya, J., Rodrigo, R., Araya, A. V., Smok, G., Csendes, A., Gutierrez, L., Rojas, J., Korn, O., et al. (2009) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2009.08.015 · Cited by 229
Mechanisms of cytochrome P‐450 catalysis
Guengerich, F. P., & Macdonald, T. L. (1990) · The FASEB Journal · doi:10.1096/fasebj.4.8.2185971 · Cited by 225
Jover, R., Bort, R., Gómez‐Lechón, M. J., & Castell, J. V. (2002) · The FASEB Journal · doi:10.1096/fj.02-0195fje · Cited by 221
Nakata, K., Tanaka, Y., Nakano, T., Adachi, T., Tanaka, H., Kaminuma, T., & Ishikawa, T. (2006) · Drug Metabolism and Pharmacokinetics · doi:10.2133/dmpk.21.437 · Cited by 215
Bazick, J., Donithan, M., Neuschwander-Tetri, B. A., Kleiner, D., Brunt, E. M., Wilson, L., Doo, E., Lavine, J., Tonascia, J., & Loomba, R. (2015) · Diabetes Care · doi:10.2337/dc14-1239 · Cited by 206
4β‐hydroxycholesterol, an endogenous marker of CYP3A4/5 activity in humans
Diczfalusy, U., Nylén, H., Elander, P., & Bertilsson, L. (2011) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.2010.03773.x · Cited by 202
Edginton, A. N., & Willmann, S. (2008) · Clinical Pharmacokinetics · doi:10.2165/00003088-200847110-00005 · Cited by 200
Hardwick, R. N., Fisher, C. D., Canet, M. J., Lake, A. D., & Cherrington, N. J. (2010) · Drug Metabolism and Disposition · doi:10.1124/dmd.110.035006 · Cited by 200
Consequences of Lipid Droplet Coat Protein Downregulation in Liver Cells
Bell, M., Wang, H., Chen, H., McLenithan, J. C., Gong, D.-W., Yang, R.-Z., Yu, D., Fried, S. K., Quon, M. J., Londos, C., et al. (2008) · Diabetes · doi:10.2337/db07-1383 · Cited by 199
Diabetes mellitus increases the in vivo activity of cytochrome P450 2E1 in humans
Wang, Z., Hall, S. D., Maya, J. F., Li, L., Asghar, A., & Gorski, J. C. (2003) · British Journal of Clinical Pharmacology · doi:10.1046/j.1365-2125.2003.01731.x · Cited by 197
Drug metabolism alterations in nonalcoholic fatty liver disease
Merrell, M. D., & Cherrington, N. J. (2011) · Drug Metabolism Reviews · doi:10.3109/03602532.2011.577781 · Cited by 181
Cytochrome P450 Regulation and Drug Biotransformation During Inflammation and Infection
Renton, K. (2004) · Current Drug Metabolism · doi:10.2174/1389200043335559 · Cited by 179
Acetaminophen‐induced liver injury in obesity and nonalcoholic fatty liver disease
Michaut, A., Moreau, C., Robin, M., & Fromenty, B. (2014) · Liver International · doi:10.1111/liv.12514 · Cited by 171
Effect of Diabetes Mellitus on Pharmacokinetic and Pharmacodynamic Properties of Drugs
Dostálek, M., Akhlaghi, F., & Puzanovova, M. (2012) · Clinical Pharmacokinetics · doi:10.1007/bf03261926 · Cited by 171
Self-citationHuman CYP2E1 is regulated by miR-378
Mohri, T., Nakajima, M., Fukami, T., Takamiya, M., Aoki, Y., & Yokoi, T. (2010) · Biochemical Pharmacology · doi:10.1016/j.bcp.2009.11.015 · Cited by 167
Brunt, E. M., Neuschwander-Tetri, B. A., Oliver, D., Wehmeier, K. R., & Bacon, B. R. (2004) · Human Pathology · doi:10.1016/j.humpath.2004.04.017 · Cited by 167
What about non-alcoholic fatty liver disease as a new criterion to define metabolic syndrome?
Tarantino, G. (2013) · World Journal of Gastroenterology · doi:10.3748/wjg.v19.i22.3375 · Cited by 166
Persico, M., Capasso, M., Persico, E., Svelto, M., Russo, R., Spano, D., Crocè, L., La Mura, V., Moschella, F., Masutti, F., et al. (2007) · Hepatology · doi:10.1002/hep.21782 · Cited by 165
Developmental Changes in Human Liver CYP2D6 Expression
Stevens, J. C., Marsh, S. A., Zaya, M. J., Regina, K. J., Divakaran, K., Le, M., & Hines, R. N. (2008) · Drug Metabolism and Disposition · doi:10.1124/dmd.108.021873 · Cited by 164
CYP3A Activity and Expression in Nonalcoholic Fatty Liver Disease
Woolsey, S., Mansell, S. E., Kim, R. B., Tirona, R. G., & Beaton, M. D. (2015) · Drug Metabolism and Disposition · doi:10.1124/dmd.115.065979 · Cited by 158
Cusi, K. J. (2016) · Diabetologia · doi:10.1007/s00125-016-3952-1 · Cited by 151
Donato, M. T., Lahoz, A., Jiménez, N., et al. (2006) · Drug Metabolism and Disposition · doi:10.1124/dmd.106.009670 · Cited by 144
Dostálek, M., Court, M. H., Yan, B., & Akhlaghi, F. (2011) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2011.01270.x · Cited by 139
Self-citationThe Effect of Liver Cirrhosis on the Regulation and Expression of Drug Metabolizing Enzymes
Elbekai, R. H., Korashy, H. M., & El‐Kadi, A. O. S. (2004) · Current Drug Metabolism · doi:10.2174/1389200043489054 · Cited by 139
Insulin resistance: the fundamental trigger of type 2 diabetes
Groop, L. (1999) · Diabetes Obesity and Metabolism · doi:10.1046/j.1463-1326.1999.0010s1001.x · Cited by 137
Johns, D. G. (1967) · Journal of Clinical Investigation · doi:10.1172/jci105641 · Cited by 136
The dual function of hepatic SOCS3 in insulin resistance in vivo
Torisu, T., Sato, N., Yoshiga, D., Kobayashi, T., Yoshioka, T., Mori, H., Iida, M., & Yoshimura, A. (2007) · Genes to Cells · doi:10.1111/j.1365-2443.2007.01044.x · Cited by 132
Elens, L., Becker, M. L., Haufroid, V., Albert Hofman, D., Visser, L. E., Uitterlinden, A. G., Stricker, B. H. C., & van Schaik, R. H. N. (2011) · Pharmacogenetics and Genomics · doi:10.1097/fpc.0b013e32834c6edb · Cited by 129
Nonalcoholic steatohepatitis: cirrhosis, hepatocellular carcinoma, and burnt-out NASH
Yoshioka, Y., Hashimoto, E., Yatsuji, S., Kaneda, H., Taniai, M., Tokushige, K., & Shiratori, K. (2004) · Journal of Gastroenterology · doi:10.1007/s00535-004-1475-x · Cited by 119
Risk of Cancer in Patients Hospitalized With Fatty Liver
Sørensen, H. T., Mellemkjær, L., Jepsen, P., Thulstrup, A. M., Baron, J. A., Olsen, J. H., & Vilstrup, H. (2003) · Journal of Clinical Gastroenterology · doi:10.1097/00004836-200304000-00015 · Cited by 119
George, J., Liddle, C., Murray, M. T., Byth, K., & Farrell, G. C. (1995) · Biochemical Pharmacology · doi:10.1016/0006-2952(94)00515-n · Cited by 117
Lucas, D., Farez, C., Bardou, L., Vaisse, J., Attali, J., & Valensi, P. E. (1998) · Fundamental and Clinical Pharmacology · doi:10.1111/j.1472-8206.1998.tb00985.x · Cited by 115
Alimentary regimen in non-alcoholic fatty liver disease: Mediterranean diet
Abenavoli, L., Milic, N., Peta, V., Alfieri, F., Lorenzo, A. D., & Bellentani, S. (2014) · World Journal of Gastroenterology · doi:10.3748/wjg.v20.i45.16831 · Cited by 114
Lean non-alcoholic fatty liver disease (Lean-NAFLD): a major cause of cryptogenic liver disease.
Vos, B., Moreno, C., Nagy, N., Féry, F., Cnop, M., Vereerstraeten, P., Deviere, J. M. E., & Adler, M. (2011) · PubMed · Cited by 99
Mediterranean diet and nonalcoholic fatty liver disease: molecular mechanisms of protection
Godos, J., Federico, A., Dallio, M., & Scazzina, F. (2016) · International Journal of Food Sciences and Nutrition · doi:10.1080/09637486.2016.1214239 · Cited by 98
Gender difference in ifosfamide metabolism by human liver microsomes
Schmidt, R., Baumann, F., Hanschmann, H., Geißler, F., & Preiß, R. (2001) · European Journal of Drug Metabolism and Pharmacokinetics · doi:10.1007/bf03190396 · Cited by 93
Unsaturated fatty acid regulation of cytochrome P450 expression via a CAR-dependent pathway
Finn, R. D., Henderson, C. J., Scott, C. L., & Wolf, C. R. (2008) · Biochemical Journal · doi:10.1042/bj20080740 · Cited by 93
Jover, R., Moya, M., & Gómez‐Lechón, M. J. (2009) · Current Drug Metabolism · doi:10.2174/138920009788898000 · Cited by 92
Association Between Nonalcoholic Hepatic Steatosis and Hepatic Cytochrome P-450 3A Activity
Kolwankar, D., Vuppalanchi, R., Ethell, B. T., Jones, D. R., Wrighton, S. A., Hall, S. D., & Chalasani, N. (2007) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2006.12.021 · Cited by 91
Altered morphine glucuronide and bile acid disposition in patients with nonalcoholic steatohepatitis
Ferslew, B. C., Johnston, C., Tsakalozou, E., Bridges, A. S., Paine, M., Jia, W. P., Stewart, P., Barritt, A. S., & Brouwer, K. L. R. (2015) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.66 · Cited by 90
Corey, K. E., Klebanoff, M. J., Tramontano, A. C., Chung, R. T., & Hur, C. (2016) · Digestive Diseases and Sciences · doi:10.1007/s10620-016-4044-2 · Cited by 84
Molecular Interactions between NAFLD and Xenobiotic Metabolism
Naik, A., Belič, A., Zanger, U. M., & Rozman, D. (2013) · Frontiers in Genetics · doi:10.3389/fgene.2013.00002 · Cited by 84
Roth, A. B., Looser, R., Kaufmann, M., & Meyer, U. (2008) · Pharmacogenetics and Genomics · doi:10.1097/fpc.0b013e3282f706e0 · Cited by 78
Drug Transporters: Their Role and Importance in the Selection and Development of New Drugs
Mizuno, N., & Sugiyama, Y. (2002) · Drug Metabolism and Pharmacokinetics · doi:10.2133/dmpk.17.93 · Cited by 75
Matzke, G. R., Frye, R. F., Early, J. J., Straka, R. J., & Carson, S. W. (2000) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1592/phco.20.3.182.34775 · Cited by 75
Canet, M. J., Merrell, M. D., Hardwick, R. N., Bataille, A. M., Campion, S. N., Ferreira, D. W., Xanthakos, S. A., Manautou, J. E., A‐Kader, H. H., Erickson, R. P., et al. (2015) · Drug Metabolism and Disposition · doi:10.1124/dmd.114.062703 · Cited by 73
Martinez‐Jimenez, C. P., Gómez-Lechón, M. J., Castell, J. V., & Jover, R. (2005) · Molecular Pharmacology · doi:10.1124/mol.104.008169 · Cited by 73
Kim, Y. C., Lee, A. K., Lee, J. H., Lee, I., Lee, D., Kim, S. H., Kim, S. G., & Lee, M. G. (2005) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2005.05.004 · Cited by 72
Canet, M. J., Hardwick, R. N., Lake, A. D., Dzierlenga, A. L., Clarke, J., & Cherrington, N. J. (2014) · Drug Metabolism and Disposition · doi:10.1124/dmd.113.055996 · Cited by 72
Role of Human GlutathioneS-Transferases in the Inactivation of Reactive Metabolites of Clozapine
Dragović, S., Boerma, J. S., van Bergen, L., Vermeulen, N. P. E., & Commandeur, J. N. M. (2010) · Chemical Research in Toxicology · doi:10.1021/tx100131f · Cited by 68
Downregulation of Sulfotransferase Expression and Activity in Diseased Human Livers
Yalcin, E. B., More, V. R., Neira, K. L., Lu, Z. J., Cherrington, N. J., Slitt, A. L., & King, R. J. (2013) · Drug Metabolism and Disposition · doi:10.1124/dmd.113.050930 · Cited by 67
Induction of CYP2E1 in non-alcoholic fatty liver diseases
Aljomah, G., Baker, S. S., Liu, W., Kozielski, R., Oluwole, J., Lupu, B., Baker, R. D., & Zhu, L. (2015) · Experimental and Molecular Pathology · doi:10.1016/j.yexmp.2015.11.008 · Cited by 66
Stepanova, M., Hossain, N., Afendy, A., Perry, K., Goodman, Z. D., Baranova, A. V., & Younossi, Z. M. (2010) · Obesity Surgery · doi:10.1007/s11695-010-0078-2 · Cited by 62
Drug metabolizing enzyme induction pathways in experimental non-alcoholic steatohepatitis
Fisher, C. D., Jackson, J. P., Lickteig, A. J., Augustine, L. M., & Cherrington, N. J. (2008) · Archives of Toxicology · doi:10.1007/s00204-008-0312-z · Cited by 59
Mechanistic Basis of Altered Morphine Disposition in Nonalcoholic Steatohepatitis
Dzierlenga, A. L., Clarke, J., Hargraves, T. L., Ainslie, G. R., Vanderah, T. W., Paine, M. F., & Cherrington, N. J. (2014) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.114.220764 · Cited by 55
Liu, F., Song, X., Yang, D., Deng, R., & Yan, B. (2007) · Biochemical Journal · doi:10.1042/bj20070613 · Cited by 53
Barnett, C. R., Abbott, R. A., Bailey, C. J., Flatt, P. R., & Ioannides, C. (1992) · Biochemical Pharmacology · doi:10.1016/0006-2952(92)90724-w · Cited by 49
Roe, A. L., Howard, G., Blouin, R. A., & Snawder, J. E. (1999) · International Journal of Obesity · doi:10.1038/sj.ijo.0800756 · Cited by 48
Impaired Microsomal Oxidation of the Atypical Antipsychotic Agent Clozapine in Hepatic Steatosis
Zhang, W. V., Ramzan, I. M., & Murray, M. T. (2007) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.107.124024 · Cited by 46
Sotaniemi, E. A., Pelkonen, O., Arranto, A. J., Tapanainen, P. J., Rautio, A., & Pasanen, M. (2002) · Pharmacology & Toxicology · doi:10.1034/j.1600-0773.2002.900308.x · Cited by 42
Dostálek, M., Court, M. H., Hazarika, S., et al. (2010) · Drug Metabolism and Disposition · doi:10.1124/dmd.110.036608 · Cited by 42
Gao, J., Zhou, J., He, X.-P., Zhang, Y., Gao, N., Tian, X., Fang, Y., Wen, Q., Jia, L.-J., Jin, H., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.8704 · Cited by 42
Toxicity of diazinon and its metabolites increases in diabetic rats
Ueyama, J., Wang, D., Kondo, T., Saito, I., Takagi, K., Takagi, K., Kamijima, M., Nakajima, T., Miyamoto, K., Wakusawa, S., et al. (2007) · Toxicology Letters · doi:10.1016/j.toxlet.2007.03.010 · Cited by 41
In vivo cytochrome P450 activity alterations in diabetic nonalcoholic steatohepatitis mice
Li, H., Clarke, J., Dzierlenga, A. L., Bear, J., Goedken, M. J., & Cherrington, N. J. (2016) · Journal of Biochemical and Molecular Toxicology · doi:10.1002/jbt.21840 · Cited by 39
Mechanism of Altered Metformin Distribution in Nonalcoholic Steatohepatitis
Clarke, J., Dzierlenga, A. L., Nelson, N. R., Li, H., Werts, S. J., Goedken, M. J., & Cherrington, N. J. (2015) · Diabetes · doi:10.2337/db14-1947 · Cited by 36
Woolsey, S., Beaton, M. D., Mansell, S. E., Leon‐Ponte, M., Yu, J., Pin, C. L., Adams, P. C., Kim, R. B., & Tirona, R. G. (2016) · Molecular Pharmacology · doi:10.1124/mol.116.104687 · Cited by 33
Dostálek, M., Sam, W. J., Paryani, K. R., Macwan, J. S., Gohh, R., & Akhlaghi, F. (2012) · Clinical Pharmacokinetics · doi:10.1007/bf03261933 · Cited by 32
Self-citationFisher, M. B., Yoon, K., Vaughn, M. L., Strelevitz, T. J., & Foti, R. (2002) · Drug Metabolism and Disposition · doi:10.1124/dmd.30.10.1087 · Cited by 30
Lee, D. Y., Lee, M. G., Shin, H. S., & Lee, I. (2007) · Journal of Pharmacy & Pharmaceutical Sciences · doi:10.18433/j3wc7g · Cited by 30
Hanagama, M., Inoue, H., Kamiya, M., Shinone, K., & Nata, M. (2008) · Legal Medicine · doi:10.1016/j.legalmed.2007.12.006 · Cited by 25
Effects of Fatty Acids on CYP2A5 and Nrf2 Expression in Mouse Primary Hepatocytes
Cui, Y., Wang, Q., Yi, X., & Zhang, X. (2015) · Biochemical Genetics · doi:10.1007/s10528-015-9697-6 · Cited by 18
Pharmacokinetics of oltipraz in rat models of diabetes mellitus induced by alloxan or streptozotocin
Bae, S. K., Kim, J. Y., Yang, S., Kim, J. W., Kim, T., & Lee, M. G. (2005) · Life Sciences · doi:10.1016/j.lfs.2005.09.031 · Cited by 16
Altered pharmacokinetics of rosiglitazone in a mouse model of non-alcoholic fatty liver disease
Kulkarni, N. M., Malampati, S., Mahat, M. Y. A., Chandrasekaran, S., Raghul, J., Khan, A. A., Krishnan, U. M., & Narayanan, S. (2016) · Drug Metabolism and Personalized Therapy · doi:10.1515/dmpt-2016-0008 · Cited by 14
Cited by
Apoptosis and necroptosis in the liver: a matter of life and death
Schwabe, R. F., & Luedde, T. (2018) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-018-0065-y · Cited by 582
Association of Inflammatory Cytokines With Non-Alcoholic Fatty Liver Disease
Duan, Y., Pan, X., Luo, J., Xiao, X., Li, J., Bestman, P. L., & Luo, M. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.880298 · Cited by 358
Changes in Glutathione Content in Liver Diseases: An Update
Vairetti, M., Di Pasqua, L. G., Cagna, M., Richelmi, P., Ferrigno, A., & Berardo, C. (2021) · Antioxidants · doi:10.3390/antiox10030364 · Cited by 313
Yang, J., Fernández-Galilea, M., Martínez-Fernández, L., González-Muniesa, P., Pérez-Chávez, A., Martínez, J. A., & Moreno-Aliaga, M. J. (2019) · Nutrients · doi:10.3390/nu11040872 · Cited by 292
Nutrition, inflammation and liver-spleen axis
Barrea, L., Di Somma, C., Muscogiuri, G., Tarantino, G., Tenore, G. C., Orio, F., Colao, A., & Savastano, S. (2018) · Critical Reviews in Food Science and Nutrition · doi:10.1080/10408398.2017.1353479 · Cited by 263
Metadata
- Authors
- Cobbina, E., & Akhlaghi, F.
- Venue
- Drug Metabolism Reviews
- Publisher
- Informa UK Limited
- Published
- 2017-03-17
- Volume
- 49
- Issue
- 2
- Pages
- 197-211
- ISSN
- 0360-2532 (ISSN-L)
- 1097-9883
- OpenAlex
- W2588823181
- Cited by
- 653
- References
- 161
- FWCI
- 31.18
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.